Comparing the current results to its competitors, Biophytis Sa reported Revenue increase in the 4 quarter 2023 by 0 % year on year, while most of its competitors have experienced contraction in revenues by -3.22 %, achieved in the same quarter.
Biophytis Sa, slower than the average decrease reported by the company's competitors of -42.14 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -42.14 %
Biophytis Sa's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical industry, which is characterized by rapid technological advancements and a focus on proprietary products. It competes with major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic institutions, governmental agencies, and public and private research organizations. Competitors may possess greater financial resources and expertise in research and development, manufacturing, clinical trials, regulatory approvals, marketing, recruitment of qualified personnel, establishment of clinical trial sites, patient registration, and acquisition of complementary technologies. Industry mergers and acquisitions may lead to resource concentration among fewer competitors. Smaller or early-stage companies also represent significant competition.
Esperion Therapeutics Inc's business model focuses on the development and commercialization of innovative therapies for addressing cardiovascular diseases.
Veru Inc operates as a pharmaceutical company primarily focused on developing and commercializing medicines for men's and women's health. With a combination of in-house research and partnerships, Veru Inc aims to address unmet medical needs by providing innovative therapies and products. Their business model encompasses both the development of new pharmaceuticals and the marketing and distribution of their existing products in the healthcare market.
Immunoprecise Antibodies Ltd operates as a contract research organization specializing in the discovery and development of therapeutic antibodies to advance the treatment of various diseases. Through customized antibody solutions and a comprehensive portfolio of services, they offer support to pharmaceutical and biotechnology companies to accelerate their drug development processes.
Biomarin Pharmaceutical Inc operates as a biotechnology company, specializing in the development and commercialization of innovative therapies for rare genetic diseases. Their business model revolves around conducting extensive research and development to identify and address unmet medical needs, manufacturing and marketing their approved products, and collaborating with strategic partners to maximize the reach and impact of their therapies worldwide. By focusing on rare diseases, Biomarin leverages their expertise to provide targeted and innovative treatments, ultimately improving the lives of patients in need.
Novan Inc is a biotechnology company that operates on a dermatology-focused business model. They develop and commercialize innovative therapies that address unmet medical needs in dermatology by utilizing their proprietary nitric oxide technology platform. Novan Inc primarily focuses on developing topical treatments for a range of skin conditions such as acne, atopic dermatitis, and fungal infections.
Sources:
Biophytis Sa’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Biophytis Sa versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
